These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 965129)

  • 41. Role of buprenorphine in the management of heroin addiction.
    Sung S; Conry JM
    Ann Pharmacother; 2006 Mar; 40(3):501-5. PubMed ID: 16434562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buprenorphine in the treatment of opioid dependence.
    George S; Day E
    Br J Hosp Med (Lond); 2007 Nov; 68(11):594-7. PubMed ID: 18087846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heroin detoxification with a single high dose of buprenorphine.
    Kutz I; Reznik V
    Isr J Psychiatry Relat Sci; 2002; 39(2):113-9. PubMed ID: 12227226
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Narcotic antagonists: naltrexone progress report: foreword.
    Jaffe J
    NIDA Res Monogr; 1976 Sep; (9):v-vii. PubMed ID: 1088898
    [No Abstract]   [Full Text] [Related]  

  • 45. Heroin: life, death, and politics.
    Jacobson J
    Am J Nurs; 2014 May; 114(5):22-3. PubMed ID: 24759473
    [No Abstract]   [Full Text] [Related]  

  • 46. Heroin and naloxone.
    Lagoy A
    Am J Nurs; 2014 Oct; 114(10):12. PubMed ID: 25251107
    [No Abstract]   [Full Text] [Related]  

  • 47. [Substitution study. Is it allowed to give placebos to junkies?].
    Ullmann R
    MMW Fortschr Med; 2003 Jul; 145(27-28):13. PubMed ID: 14587179
    [No Abstract]   [Full Text] [Related]  

  • 48. Predictors of the severity of depressive symptoms among intravenous heroin users receiving methadone maintenance treatment in Taiwan: an 18-month follow-up study.
    Wang PW; Wu HC; Yen CN; Yeh YC; Chung KS; Chang HC; Yen CF
    Psychol Addict Behav; 2012 Mar; 26(1):145-50. PubMed ID: 21859169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.
    Negus SS; Banks ML
    Pharmacol Biochem Behav; 2018 Jan; 164():32-39. PubMed ID: 28442370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy].
    Roozen HG; Deden AL; Kerkhof AJ; Vorsteveld JP; van den Brink W
    Ned Tijdschr Geneeskd; 1997 Dec; 141(49):2377-80. PubMed ID: 9554156
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methadone maintenance and narcotic blocking drugs. Appendix.
    Wikler A
    Int J Addict; 1977 Oct; 12(7):869-81. PubMed ID: 338517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regarding naltrexone for probationers and parolees.
    Stancliff S
    J Subst Abuse Treat; 2007 Mar; 32(2):217-8; author reply 218-9. PubMed ID: 17306730
    [No Abstract]   [Full Text] [Related]  

  • 53. A clinical trial of buprenorphine: I. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties.
    Bickel WK; Johnson RE; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR
    NIDA Res Monogr; 1987; 76():182-8. PubMed ID: 2449618
    [No Abstract]   [Full Text] [Related]  

  • 54. Methadone maintenance and narcotic blocking drugs.
    Wikler A
    Int J Addict; 1977 Oct; 12(7):851-6. PubMed ID: 201577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A possibility of the use of low naloxone dosages in the treatment of heroin dependence].
    Nadezhdin AV; Litvinova SV; Tetenova EIu; Mikhalev IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(1):56-7. PubMed ID: 16457136
    [No Abstract]   [Full Text] [Related]  

  • 56. Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use.
    Longshore D; Annon J; Anglin MD; Rawson RA
    Addiction; 2005 Aug; 100(8):1131-9. PubMed ID: 16042643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis].
    Levasseur L; Marzo JN; Ross N; Blatier C
    Ann Med Interne (Paris); 2002 May; 153(3 Suppl):1S14-9. PubMed ID: 12218878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Naltrexone for probationers and parolees.
    O'Brien C; Cornish JW
    J Subst Abuse Treat; 2006 Sep; 31(2):107-11. PubMed ID: 16919734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What heroin users tell us about overdose.
    Baca CT; Grant KJ
    J Addict Dis; 2007; 26(4):63-8. PubMed ID: 18032233
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psychopathology and mood during heroin use: acute vs chronic effects.
    Mirin SM; Meyer RE; McNamee HB
    Arch Gen Psychiatry; 1976 Dec; 33(12):1503-8. PubMed ID: 999452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.